Evidence map›Paper›PMID 27039125›Full record

Trial reportJACC. Heart failure2016

Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

John J Lepore, Eric Olson, Laura Demopoulos, Thomas Haws, Zixing Fang, April M Barbour, Michael Fossler, Victor G Davila-Roman, Stuart D Russell, Robert J Gropler

2 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in JACC. Heart failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 71 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 9 pooled it
13.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05478707 phase2recruitingstarted 2023, after this paper: background citation

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Ran2023Enrolled47Registered outcomes5Posted comparisons0ConditionsDiabetes Mellitus, Type 1, Endothelial DysfunctionArmsDulaglutide, Placebo
PMID 29310645PMID 24742660PMID 22732108PMID 27295427PMID 27436611PMID 27633186PMID 28817231PMID 28386795PMID 27506222PMID 27493132PMID 26936306PMID 26739816other papers from this trial
Open the trial in the graph
NCT01357850 phase2completednot on this map

A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure

TypeinterventionalSponsorGlaxoSmithKlineRan2010 to 2012Enrolled82ConditionsHeart Failure, CongestiveArmsGSK716155, Placebo
3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 9 syntheses or guidelines pooled it, 166 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Review
  20. GLP-1 and the cardiovascular system.The Journal of clinical investigation · 2026
    Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

John J LeporeMetabolic Pathways and Cardiovascular Therapeutic Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania. Electronic address: john.j.lepore@gsk.com.
Eric OlsonMetabolic Pathways and Cardiovascular Therapeutic Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania.
Laura DemopoulosMetabolic Pathways and Cardiovascular Therapeutic Area Unit, GlaxoSmithKline, King of Prussia, Pennsylvania.
Thomas HawsClinical Pharmacology Science and Study Operations, GlaxoSmithKline, King of Prussia, Pennsylvania.
Zixing FangQuantitative Sciences, Clinical Statistics, GlaxoSmithKline, King of Prussia, Pennsylvania.
April M BarbourClinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania.
Michael FosslerClinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania.
Victor G Davila-RomanCardiovascular Imaging and Clinical Research Core Laboratory, Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Stuart D RussellDivision of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
Robert J GroplerMallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri.
GlaxoSmithKline (United States) · USPathways Behavioral Services · USGlaxoSmithKline (United Kingdom) · GBJohns Hopkins University · USMallinckrodt (United States) · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study sought to determine if glucagon-like peptide (GLP)-1 ameliorates myocardial metabolic abnormalities in chronic heart failure.

backgroundAlbiglutide (GSK716155) is a GLP-1 agonist indicated for type 2 diabetes.

methodsWe performed a randomized, placebo-controlled study evaluating 12 weeks of albiglutide in New York Heart Association II or III subjects with ejection fraction <40%. Subjects received weekly placebo (n = 30) or albiglutide 3.75 mg (n = 12), 15 mg (n = 13), or 30 mg (n = 27). The primary comparison was between albiglutide 30 mg and placebo. Assessments included echocardiography, 6-minute-walk test, and peak oxygen consumption. In a subgroup of patients, myocardial glucose and oxygen use were assessed. Endpoints are reported as change from baseline ± SE.

resultsAlbiglutide 30 mg compared with placebo did not improve change from baseline in left ventricular ejection fraction (2.4% [1.1%] vs. 4.4% [1.1%]; p = 0.22), 6-min walk test (18 [12] m vs. 9 [11] m; p = 0.58), myocardial glucose use (p = 0.59), or oxygen use (p = 0.25). In contrast, albiglutide 30 mg versus placebo improved change from baseline in peak oxygen consumption (0.9 [0.5] ml/kg/min vs. -0.6 [0.5] ml/kg/min; p = 0.02). Albiglutide was well tolerated.

conclusionsAlthough there was no detectable effect of albiglutide on cardiac function or myocardial glucose use, there was a modest increase in peak oxygen consumption, which could have been mediated by noncardiac effects. (A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure; NCT01357850).

Indexed as

Exercise ToleranceStroke VolumeAdultAgedCarbon RadioisotopesChronic DiseaseEchocardiographyFemaleFluorodeoxyglucose F18Glucagon-Like Peptide 1GlucoseHeart FailureHumansIncretinsMaleMiddle AgedCarbon RadioisotopesFluorodeoxyglucose F18Glucagon-Like Peptide 1GlucoseIncretinsRadiopharmaceuticalsrGLP-1 proteinalbiglutideglucagon-like peptide-1 (GLP-1)heart failure

Identifiers

PMID27039125
OpenAlexW2335779504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.